Our Hoofing IT Champions:
HOOFING IT! 2026 Total Raised $31,515
2026 Campaign: Hoofing IT 2026 raised $31,515 for NET cancer research!
Thank you to all our donors!
Final Results
HOOFING IT! 2026:
Raised $31,515!
Thank you to all our donors!

ESMO 2016 NET News

Clinical benefit demonstrated with everolimus and pasireotide LAR alone or in combination in the first randomised, prospective study entirely dedicated to advanced lung and thymic carcinoids. In patients with advanced [...]

By |2018-05-07T18:28:12-04:00October 13th, 2016|Clinical Trial, News, Treatment News|Comments Off on ESMO 2016 NET News

New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors

A Prospective Single-Arm, Multi-Centre, Study of the Efficacy and Safety of Lutetium-177 Octreotate (Lu-DOTATATE) Treatment With Individualized Dosimetry in Patients With 68Ga-DOTATATE Identified Somatostatin Receptor Positive Neuroendocrine Tumors Not yet [...]

By |2018-05-07T18:28:13-04:00June 5th, 2016|Clinical Trial|Comments Off on New NET Clinical Trial in Canada – Lu-DOTATATE Treatment in Patients With 68Ga-DOTATATE Somatostatin Receptor Positive Neuroendocrine Tumors
Go to Top